Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

Roswell Park Cancer Institute26 enrolled

Overview

This trial studies the main and interactive effects of episodic future thinking and future thinking priming tasks on helping participants to quit smoking. Episodic future thinking and future thinking priming tasks may decrease delay discounting rates and reduce relapse to smoking and help participants quit smoking.

PRIMARY OBJECTIVE: I. To quantify the main and interactive effects of the episodic future thinking (EFT) and future thinking priming (FTP) tasks on delay discounting rate, latency to relapse, and multiple abstinence and self-regulation measures among smokers (n=76) who call a busy Quitline to quit smoking. OUTLINE: Participants are randomized to 1 of 4 arms. ARM I: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks. ARM II: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks. ARM III: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks. ARM IV: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Tobacco-Related Carcinoma

Interventions

Behavioral InterventionBEHAVIORAL

Complete active episodic thinking task

Behavioral InterventionBEHAVIORAL

Complete active future thinking priming task

Behavioral InterventionBEHAVIORAL

Complete control episodic future thinking task

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Smoke \>= 8 cigarettes daily * Planning to quit in the next 14 days * No regular use of other tobacco products * Access to the internet * In possession of a smartphone with text messaging capabilities * In possession of an email address accessible at least every other day Exclusion Criteria: * Unable or unwilling to provide consent * Unable to provide data to the research team after the quit date * Current use of bupropion or varenicline * Drinking \>= 20 alcoholic drinks per week * Use of drugs of abuse in the past 30 days * Living in the same household as a participant already enrolled in this study

Locations (1)

Roswell Park Cancer Institute

Buffalo, New York, United States

Outcomes

Primary Outcomes

Change in Delay discounting rate

Assessed with the 5-Trial Adjusting Delay Discounting.

Time frame: Baseline, and 4 and 12 weeks after quit date

Latency to relapse

Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.

Time frame: Baseline, assessed up to 12 weeks

Secondary Outcomes

Latency to first relapse

Defined as the number of days until first relapse (any smoking for seven consecutive days). Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.

Time frame: up to 12 weeks

Number of days abstinent

Will be evaluated by cox proportional-hazards survival model analyses.

Time frame: Up to 12 weeks

7-day point prevalence abstinence rates

Will be evaluated by cox proportional-hazards survival model analyses.

Time frame: At 4 and 12 weeks after quit date

Attentional, motor, and non-planning impulsiveness

Assessed with the Barratt Impulsiveness Scale.

Time frame: Up to 12 weeks

Behavioral inhibition and behavioral activation

Assessed with the Behavioral Avoidance/Inhibition scales.

Time frame: Up to 12 weeks

Self-control

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.